It is reported that ITGAV silencing inhibits cell proliferation, invasion and self-renewal of breast cancer cell lines by altering the expression of BCL2 apoptosis regulator (BCL2) and paxillin (PXN) (Cheuk et al., 2020). This evidence concerns the gene ITGAV and breast cancer.